The tragedy of the cancer-influencer economy

Sydney Towle, a 26-year-old who documented her battle with a rare bile duct cancer on TikTok, died on August 5th. Her family announced the news on her social media channels the next day, with a caption describing her as an "endless ray of sunshine". Her followers, more than a million of them, responded as one expects they will. Ms Towle's death is a human tragedy. It also illuminates a structural problem that social media platforms have done little to solve: the incentive system that turns illness into content, and recovery into irrelevance.

Ms Towle was diagnosed with cholangiocarcinoma in 2023. Cholangiocarcinoma is a rare cancer of the bile ducts that is often asymptomatic in its early stages and frequently diagnosed only after it has spread. The five-year survival rate for distant disease—the category into which Ms Towle's cancer had progressed—is between 2% and 3%, according to the American Cancer Society. She survived for three years, which was longer than the median.

Before her diagnosis, Ms Towle posted lifestyle content. After she announced her cancer, her following grew to more than a million. She chronicled chemotherapy appointments, symptom management, and moments of respite, including scuba diving. She maintained a posture of hope. Her brother Austin announced she had entered hospice care on August 4th.

What Ms Towle's story illustrates is not simply the nobility of a young woman facing a nearly hopeless diagnosis. It is the mechanics of an attention economy that has learned to monetise suffering. The evidence for this is now substantial. A June 2026 profile in Business Insider by Sarah Barness, herself a former cancer influencer, documented the dynamic in uncomfortable detail. The profile documented how engagement peaks during visible illness and drops during recovery.

The perverse part comes next. As patients recover and their illness becomes less visible, engagement drops. Recovery, the thing everyone claims to want for the patient, looks like irrelevance to the algorithm. The result is an unspoken pressure on patients to recycle old sick content, repost bald photos, and linger in a trauma identity that once felt like community and starts to feel like a trap.

To be sure, Ms Towle appears to have navigated this ecosystem in good faith. She raised funds for treatment and travel, she shared clinical trial participation, and she encouraged hope without making medical claims that could mislead followers into false optimism. She was not, as far as is known, promoting unproven therapies or selling supplements to desperate people. Her GoFundMe page, which helped cover medical expenses, was set up to support her care, not to enrich her. The cancer-influencer economy is not inherently exploitative. For patients facing isolation, the dopamine of community can be genuine.

Yet the system that rewards visible suffering cannot credibly claim neutrality. It profits from the very dynamic it encourages. In February 2025, a University of Sydney-led study published in JAMA Network Open found that the majority of health influencers had explicit financial interests, and most posts mentioned benefits while few discussed harms or risks of overdiagnosis. The lead researcher, Dr Brooke Nickel, described the information as "overwhelmingly misleading." The study did not focus on cancer influencers specifically, but the incentive structure is the same: sickness performs, health fades, and platforms collect the advertising revenue in between.

The case of Brittany Miller, a British TikTok creator who fabricated a cancer diagnosis and only apologised in November 2025, shows how easily the incentives corrupt. The fact that a false cancer diagnosis could sustain followers for years says more about the platform than about one person's desperation.

The broader lesson is institutional. Social media companies have built recommendation algorithms that optimise for engagement without accounting for the welfare of the people generating the content. When a 23-year-old with a 2% survival rate discovers that her audience grows by hundreds of thousands after she shares her diagnosis, the platform has given her something real: community, funds, a sense of purpose. It has also given her a system in which her best-case outcome—getting well—is treated as a content failure. That is not a criticism of Ms Towle or of the millions who followed her with genuine sympathy. It is a diagnosis of the machine.

Platforms could address the problem without censoring patients. They could diversify the engagement signals that promote health content, so that recovery, survivorship and advocacy are rewarded alongside acute treatment updates. They could require clearer disclosure when influencers earn revenue from sponsorships tied to medical products or fundraising. They could partner with oncology organisations to ensure that algorithmic amplification does not inadvertently promote misleading claims. None of these measures is difficult. All of them require admitting that the current system externalises its costs onto the people it most needs to protect.

Ms Towle's family deserves privacy. Her followers' grief is real. The community she built was not an illusion. But a system that asks the ill to perform and punishes the recovered is not one that deserves to be left unexamined. Better to start fixing it now, while patients are still alive to benefit from the change.